Pretreatment fat‐free mass index correlates with early death in patients with head and neck squamous cell carcinoma

Documents similaires

• Establishment of an in situ model to explore the tumor immune microenvironment in head and neck squamous cell carcinoma
  par: Congxian Lu, et autres
  Publié: (2024)
• The impact of COVID‐19 and vaccination status on outcomes in veterans with head and neck squamous cell carcinoma
  par: James D. Johns, et autres
  Publié: (2024)
• Survival and complications after carotid resection for head and neck squamous cell carcinoma: A systematic review and pooled analysis
  par: Gian Marco Pace, et autres
  Publié: (2024)
• Durvalumab in combination with chemoradiotherapy in patients with head and neck squamous cell carcinoma: Results from the Phase 1 CLOVER study
  par: Julie E. Bauman, et autres
  Publié: (2024)
• Survivin/BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma
  par: Ester Benaiges, et autres
  Publié: (2024)